Kilroy Conor 4
4 · IRONWOOD PHARMACEUTICALS INC · Filed Mar 2, 2021
Insider Transaction Report
Form 4
Kilroy Conor
SVP, GC & Secretary
Transactions
- Sale
Class A Common Stock
2021-02-26$9.11/sh−1,399$12,745→ 127,926 total - Sale
Class A Common Stock
2021-02-26$9.11/sh−2,268$20,661→ 124,184 total - Sale
Class A Common Stock
2021-02-26$9.11/sh−1,474$13,428→ 126,452 total - Sale
Class A Common Stock
2021-02-26$9.11/sh−1,848$16,835→ 122,336 total
Footnotes (5)
- [F1]This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 27, 2017.
- [F2]The reporting person acquired 492 shares of Class A common stock under the issuer's employee stock purchase plan on December 31, 2020.
- [F3]This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on March 15, 2018.
- [F4]This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on January 29, 2019.
- [F5]This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 33.33% of the reporting person's restricted stock units granted on February 27, 2020.